Ruxolitinib for the Treatment of T-Cell Large Granular Lymphocytic Leukemia

Summary

This phase II trial tests whether ruxolitinib works to shrink tumors in patients with T-cell large granular lymphocyte leukemia. Ruxolitinib may stop the growth of cancer cells by blocking some of the enzymes needed for cell growth.

Timeline

Start

2023-05-03

Primary completion

2026-07-31

Completion

2026-07-31

Drugs

Indications